Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | PDE6D | O43924 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7858415 | 1.00 | HMGCR (0.72) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL27636878 | 1.00 | HMGCR (0.72) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL9871185 | 0.85 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL9871697 | 0.85 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL9871701 | 0.85 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 0.83 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240432 | 0.83 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL16995485 | 0.83 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 0.83 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 0.83 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070938-A1 | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | SANKYO COMPANY, LIMITED (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20050187204-A1 | Medicinal composition for lowering blood lipid level | SANKYO COMPANY, LIMITED (JP) | 2005-08-25 | — | — | US | disclosed |
| US-20050182106-A1 | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | SANKYO COMPANY, LIMITED (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050182036-A1 | Medicinal composition containing an HMG-CoA reductase inhibitor | SANKYO COMPANY, LIMITED (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20040121008-A1 | Process for producing sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1369130-A1 | PROCESS FOR PRODUCING SUSTAINED RELEASE PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-20030068374-A1 | Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1258254-A1 | SUSTAINED RELEASE PREPARATIONS OF PHYSIOLOGICALLY ACTIVE COMPOUND HARDLY SOLUBLE IN WATER AND PRODUCTION PROCESS AND USE OF THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| JP-2001206877-A | PHARMACEUTICAL COMPOSITION | ASTRAZENECA AB | 2001-07-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187204-A1 | Medicinal composition for lowering blood lipid level | HMGCR, APOB, CETP | HMGCR 1/4885ALDH1A1 1280/4885CYP3A4 466/4885 |
| US-20030068374-A1 | Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same | CHERP, VMA21, ATP2A1 | HMGCR 4368/4885ALDH1A1 3851/4885CYP3A4 1535/4885 |
| US-20080070938-A1 | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | HMGCR, PLPBP, BHMT | HMGCR 1/4885ALDH1A1 1089/4885CYP3A4 238/4885 |
| US-20050182036-A1 | Medicinal composition containing an HMG-CoA reductase inhibitor | HMGCR, NR1H3, NR1H2 | HMGCR 1/4885ALDH1A1 1122/4885CYP3A4 644/4885 |
| US-20040121008-A1 | Process for producing sustained release preparation | VMA21, PUF60, SAMM50 | HMGCR 2788/4885ALDH1A1 3079/4885CYP3A4 258/4885 |
| US-20050182106-A1 | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | HMGCR, BHMT, APOB | HMGCR 1/4885ALDH1A1 773/4885CYP3A4 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.